GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (NAS:CPRX) » Definitions » Cyclically Adjusted PS Ratio

Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Cyclically Adjusted PS Ratio : 8.08 (As of Jun. 10, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Catalyst Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-06-10), Catalyst Pharmaceuticals's current share price is $15.425. Catalyst Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $1.91. Catalyst Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 8.08.

The historical rank and industry rank for Catalyst Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

CPRX' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.55   Med: 7.54   Max: 72.86
Current: 8.18

During the past years, Catalyst Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 72.86. The lowest was 3.55. And the median was 7.54.

CPRX's Cyclically Adjusted PS Ratio is ranked worse than
61.35% of 502 companies
in the Biotechnology industry
Industry Median: 5.43 vs CPRX: 8.18

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Catalyst Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.798. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.91 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Catalyst Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Catalyst Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.61 3.56 6.12 13.72 9.26

Catalyst Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.29 8.45 6.81 9.26 8.35

Competitive Comparison of Catalyst Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Catalyst Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalyst Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Catalyst Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Catalyst Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Catalyst Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=15.425/1.91
=8.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalyst Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Catalyst Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.798/131.7762*131.7762
=0.798

Current CPI (Mar. 2024) = 131.7762.

Catalyst Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.005 105.998 0.006
201903 0.121 107.251 0.149
201906 0.272 108.070 0.332
201909 0.289 108.329 0.352
201912 0.283 108.420 0.344
202003 0.273 108.902 0.330
202006 0.277 108.767 0.336
202009 0.276 109.815 0.331
202012 0.293 109.897 0.351
202103 0.283 111.754 0.334
202106 0.338 114.631 0.389
202109 0.333 115.734 0.379
202112 0.352 117.630 0.394
202203 0.395 121.301 0.429
202206 0.486 125.017 0.512
202209 0.511 125.227 0.538
202212 0.531 125.222 0.559
202303 0.749 127.348 0.775
202306 0.876 128.729 0.897
202309 0.964 129.860 0.978
202312 0.972 129.419 0.990
202403 0.798 131.776 0.798

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Catalyst Pharmaceuticals  (NAS:CPRX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Catalyst Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Executives
Molly Harper director 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
David S Tierney director C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Alicia Grande officer: Chief Accounting Officer 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Gary Ingenito officer: Chief Medical Officer 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Steve Miller officer: VP Development & Management 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Tamar Thompson director C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Patrick J Mcenany director, 10 percent owner, officer: President and Chief Executive C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Carmen Jeffrey Del officer: Chief Commercial Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Brian Elsbernd officer: Chief Compliance/Legal Officer 355 ALHAMBRA CIRCLE, CORAL GABLES FL 33134
Philip H Coelho director C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Charles B O'keeffe director 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Donald A Denkhaus director 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Preethi Sundaram officer: Chief Product Devel. Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Daniel Brennan officer: Chief Commercial Officer C/O INSYS THERAPEUTICS, INC, 1333 SOUTH SPECTRUM BLVD, SUITE 100, CHANDLER AZ 85286
M Douglas Winship officer: V.P. of Regulatory Operations 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134

Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Headlines